Inst. Holders
25 funds
KZR
Kezar Life Sciences, Inc.
—
12-mo target$6.00 (-17.7%)
High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on KZR right now — valuation, ownership and activity at a glance.
Inst. Value
$9.0M
Inst. Activity
2 buys / 1 sells
SEC Reports
3
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 11, 2026 earnings_calendar
May 15, 2026 SEC KZR Q2 2026 Earnings Scheduled — 2026-08-11
Kezar Life Sciences' registration statement on Form S-3 (File No. 333-284712) was declared effective by the SEC on May 1
EFFECT — Impact 5/10
Nasdaq filed a 25-NSE notification to remove Kezar Life Sciences' common stock from listing, effective immediately. This
25-NSE — Impact 2/10
Kezar Life Sciences has been acquired by Aurinia Pharma U.S., Inc. in a completed tender offer and merger. Shareholders
8-K — Impact 8/10
May 11, 2026 Insider
Chiang Pichi Luo disposed of 7,999 shares
SVP, Corporate Controller
May 11, 2026 Insider
Chiang Pichi Luo disposed of 4,999 shares
SVP, Corporate Controller
May 11, 2026 Insider
Chiang Pichi Luo disposed of 2,899 shares
SVP, Corporate Controller
Mar 31, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
188,426 shares ($1.4M)
Analyst ratings buy % +10.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 17, 2025 | Jefferies | DOWNGRADE | Hold | 53% |
| Oct 17, 2025 | William Blair | DOWNGRADE | Market Perform | 51% |
| Oct 17, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Jul 16, 2025 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Dec 19, 2024 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Dec 2, 2024 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Nov 14, 2024 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Oct 18, 2024 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Oct 14, 2024 | HC Wainwright & Co. | REITERATE | Neutral | 43% |
| Oct 2, 2024 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 1 | 3 | 5 | 0 | 0 | 44% | |
| Aug 1, 2026 | 1 | 3 | 5 | 0 | 0 | 44% | |
| Jul 1, 2026 | 1 | 3 | 5 | 0 | 0 | 44% | |
| Jun 1, 2026 | 1 | 3 | 5 | 0 | 0 | 44% | |
| May 1, 2026 | 1 | 3 | 5 | 0 | 0 | 44% | |
| Apr 1, 2026 | 1 | 3 | 6 | 0 | 0 | 40% | |
| Mar 1, 2026 | 1 | 3 | 6 | 0 | 0 | 40% | |
| Feb 1, 2026 | 1 | 3 | 6 | 0 | 0 | 40% |
Price targets
Where 2 covering analysts think KZR trades over the next 12 months.
$6.00 -17.7% upside Strong Sell
Current$7.29 Low$5.00 Median$6.00 High$7.00 2 analysts
$5.00$7.00
Analyst rating None as of Jul 9, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
3 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 2 neutral · avg impact 5.0/10.
BEARISHEFFECT5/10
Kezar Life Sciences' registration statement on Form S-3 (File No. 333-284712) was declared effective
May 15, 2026
NEUTRAL25-NSE2/10
Nasdaq filed a 25-NSE notification to remove Kezar Life Sciences' common stock from listing, effecti
May 11, 2026
NEUTRAL8-K8/10
Kezar Life Sciences has been acquired by Aurinia Pharma U.S., Inc. in a completed tender offer and m
May 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 11, 2026
earnings_calendar
KZR Q2 2026 Earnings Scheduled — 2026-08-11
May 11, 2026
earnings_calendar
KZR Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
KZR Q1 2026 Earnings Scheduled — 2026-05-07
Mar 12, 2026
earnings_calendar
KZR Q4 2025 Earnings After Market Close — 2026-03-12
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Next FY | $-3.96 | $-4.66–$-3.27 | 1.4% | -28.5% | 1↑ 0↓ | $0.0B | 2 |
| Current Q | $-0.91 | $-0.91–$-0.91 | 51.3% | +27.5% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-4.02 | $-4.46–$-3.58 | 40.2% | -22.9% | 1↑ 0↓ | $0.0B | 2 |
| Next Q | $-0.87 | $-0.87–$-0.87 | 43.1% | +29.6% | 1↑ 0↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.910 | — |
| 7d ago | $-0.910 | — |
| 30d ago | $-1.255 | +0.345 |
| 60d ago | $-1.255 | +0.345 |
| 90d ago | $-1.255 | +0.345 |
Institutional ownership
Which big funds own KZR (from quarterly 13F filings) and who is adding or trimming.
25 institutional holders with $9.0M total value (1,217,404 shares) as of 2026-Q1. Top holders: VANGUARD, RENAISSANCE, SUSQUEHANNA. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 290,529 | $2.2M | 23.9% | — |
| RENAISSANCE TECHNOLOGIES LLC | 188,426 | $1.4M | 15.5% | ADD +43.5% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 149,800 | $1.1M | 12.3% | — |
| MILLENNIUM MANAGEMENT LLC | 142,050 | $1.1M | 11.7% | TRIM -27.6% |
| BlackRock, Inc. | 100,064 | $742.5K | 8.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 60,988 | $452.6K | 5.0% | — |
| CITADEL ADVISORS LLC | 59,403 | $440.8K | 4.9% | TRIM -49.2% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 51,800 | $384.4K | 4.3% | — |
| VANGUARD FIDUCIARY TRUST CO | 41,201 | $305.7K | 3.4% | — |
| DIMENSIONAL FUND ADVISORS LP | 30,334 | $225.1K | 2.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 131,285 | 188,426 | +43.5% | $1.4M |
| FMR LLC | DOUBLED | 208 | 10,208 | +4807.7% | $75.7K |
| UBS Group AG | TRIM | 40 | 13 | -67.5% | $96.00 |
| VANGUARD GROUP INC | ADD | 268,166 | 341,404 | +27.3% | $2.1M |
| STATE STREET CORP | ADD | 21,093 | 27,093 | +28.4% | $170.4K |
| TWO SIGMA INVESTMENTS, LP | TRIM | 23,682 | 11,312 | -52.2% | $71.2K |
| MORGAN STANLEY | TRIM | 7,820 | 5,685 | -27.3% | $35.8K |
| FMR LLC | NEAR_EXIT | 8,732 | 208 | -97.6% | $1.3K |
| JPMORGAN CHASE & CO | TRIM | 209 | 109 | -47.8% | $686.00 |
| UBS Group AG | NEAR_EXIT | 356 | 40 | -88.8% | $252.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 7,999 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 4,999 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 2,899 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 2,499 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 2,401 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 599 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 2,052 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 1,199 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 7,500 | — | — |
| May 11, 2026 | Chiang Pichi Luo | SVP, Corporate Controller | D | 17,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KZR.
Shares short
158,519
Settlement Apr 30, 2026
Change vs prior
+4.6%
Semi-monthly cycle
Days to cover
2.3
At avg daily volume
All KZR filing & press-release reports (3)
- EFFECT reportMay 15, 2026
- 25-NSE reportMay 11, 2026
- 8-K reportMay 11, 2026